Last reviewed · How we verify

suganon tab 5mg

Yonsei University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

suganon tab 5mg is a Small molecule drug developed by Yonsei University. It is currently FDA-approved.

Suganon Tab 5mg is used to treat conditions such as Type 2 Diabetes Mellitus and Hepatitis B with significant hepatic fibrosis. However, there is limited information available on Suganon Tab 5mg, as it is not mentioned in the provided facts, and the only information available is related to Suganon Tab 15mg and evogliptin.

At a glance

Generic namesuganon tab 5mg
SponsorYonsei University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about suganon tab 5mg

What is suganon tab 5mg?

suganon tab 5mg is a Small molecule drug developed by Yonsei University.

Who makes suganon tab 5mg?

suganon tab 5mg is developed and marketed by Yonsei University (see full Yonsei University pipeline at /company/yonsei-university).

What development phase is suganon tab 5mg in?

suganon tab 5mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing